How do you like selling Fentora for Teva?

Quote


































































Can't believe it. Made it thr 1st interview!!!
Flying to meet region big wig-- week after next (KC or Penn?)

Any tips abt how to get hired to be a pain care specialist w teva/ceph??
 
























Cephalon Ordered to Pay Anchen's Attorney Fees for Maintaining Suit Despite Having No Evidence of Infringement AMRIX

In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, No. 09-MD-2118-SLR (D. Del.) / AMRIX

Under 35 U.S.C. § 285, a court may, in "exceptional cases," award attorney fees to the prevailing party. In an Order filed on January 12th, the district court presiding over the ANDA litigation involving AMRIX granted Anchen's motion for attorney fees, concluding that Cephalon's decision to maintain its suit against Anchen after it knew that Anchen's ANDA product did not infringe made the case exceptional.

Anchen filed its motion for attorney fees last May, after the district court granted final judgment of noninfringement in favor of Anchen. Anchen argued in its motion that Cephalon's suit was baseless from the start, but the court disagreed:

Plaintiffs' complaint provides the basis on which the suit was filed. Plaintiffs' complaint explains that "the Anchen Paragraph IV Notice letters . . . fail to comply with the requirements of 21 U.S.C. § 355(j)(2)(B)(iv)(II) because, inter alia, they contain very limited information about the generic formulation for which Anchen filed ANDA No. 91-281. For example, the Anchen Paragraph IV Notice letters do not list any of the ingredients in the proposed generic versions." Having been unable to come to an agreement with Anchen on the conditions under which they could procure or view a copy of ANDA No. 91-281, plaintiffs opted to file suit in order to obtain the information (and then prove that infringement was occurring as suspected).

The court decided, however, that Cephalon should have dropped its suit once it knew that Anchen's ANDA product was noninfringing. Cephalon argued that it was within its rights to maintain the suit because Anchen was proceeding to trial on a "sham" formulation, and if a final judgment of noninfringement was granted to Anchen "the Court would no longer have had jurisdiction to police Anchen's compliance with its promise not to reformulate, and Plaintiffs would have had no assurance that Anchen would not immediately reformulate its product in a manner that would infringe by, for example, simply copying Plaintiffs' product in order to obtain quick FDA approval."

Accordingly, the court granted Anchen's motion for fees. The court cited AstraZeneca v. Dr. Reddy's in support of the rule that maintenance of a suit despite a lack of evidence of infringement makes a case exceptional. The court assessed attorney fees from September 2010, "a date by which plaintiffs opted to maintain a suit with clear knowledge that Anchen's product, as formulated, did not infringe." In support of its decision to assess fees from September 2010 forward, rather than from the beginning, the court explained, "plaintiffs did not originally file a frivolous suit; the suit became unjustifiable once plaintiffs declined to acknowledge that there was no need to maintain the suit in order to police Anchen's conduct."
 






Anonymous said:
Agh, Ford Fs are so primary care-esq.
Click to expand...

Oh yes. God forbid a sales person get a company car with gas to do a job that will disappear within two years. You clown - check your ego at the door. You are a sales person, not a pro athlete, physician, entertainer, etc. Your access to the targeted customer is shrinking daily and you may be selling shoes in a couple of months. Then you can take the bus. WTF Moron!
 












Super painkiller: TD Hydrocodone to compete with Zohydro
TRACY CONNOR Thursday, January 12, 2012 NY Daily News

DESPITE WARNINGS from lawmakers and narcs, a second company has unveiled plans for a super-painkiller with four times the amount of hydrocodone as a single Vicodin tablet.

Teva Pharmaceuticals is in the final stages of testing TD Hydrocodone, which would compete with a similar pill, Zohydro, and could hit the market by year’s end.

Both pills are extended-release capsules of pure opiate, much like OxyContin — the biggest player in America’s prescription drug problem.

William Marth of Teva told investors this week that if TD Hydrocodone gets FDA approval, it could make $500 million within a couple of years.
 






Top Bottom
Back
Quote